Back to Results
First PageMeta Content
Organic chemistry / Clinical pharmacology / Amines / Serotonin-norepinephrine reuptake inhibitors / Desvenlafaxine / IntelliPharmaCeutics / Chemistry / Alcohols / Venlafaxine


SUPPLEMENTAL NEW DRUG APPLICATION – PEDIATRIC INDICATIONS BPCA SUMMARY REVIEW OFFICE OF CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS NDAs: 20-151
Add to Reading List

Document Date: 2004-06-08 09:31:22

Open Document

File Size: 68,19 KB

Share Result on Facebook

City

Philadelphia / /

Company

Wyeth / /

Event

FDA Phase / /

MedicalCondition

General Anxiety Disorder / /

Organization

office of Clinical Pharmacology / PEDIATRIC INDICATIONS BPCA SUMMARY REVIEW OFFICE OF CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS NDAs / /

Person

Anxiety Disorder / /

Position

General / EXECUTIVE / /

Product

Venlafaxine / Extended Release Capsules / Effexor / Effexor XR / IR tablet / S-029 / /

SocialTag